The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 8 of the 85 sources its claims cite were checked for support.
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US
Open accessAbstract
Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost-effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.
Overview
CoChat Summary
## TL;DR
This white paper reviews market strategies and federal policy options to improve affordable and equitable access to GLP-1 obesity medications in the US. It argues that these drugs are clinically promising but that their very large potential uptake and high ongoing costs create major coverage, pricing, and equity challenges.
## Key findings
- GLP-1 receptor agonists and GLP-1/GIP receptor agonists can produce substantial weight loss and may improve outcomes such as cardiovascular events and obstructive sleep apnea, but the paper emphasizes that long-term durability and safety for obesity treatment remain uncertain.
- The scale of the target population is very large: over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications.
- Current commercial net prices for GLP-1s used for obesity are reported at approximately $8,000–$9,000 annually in the US market, while direct-to-consumer cash prices are about $499 per month ($5,988 annually).
- The paper notes that some analysts estimate spending on this drug class could exceed $100 billion annually within 5 years; it also cites examples of major cost growth, including Blue Cross Blue Shield of Massachusetts reporting more than $300 million in GLP-1 costs in 2024 and a $400 million operating loss.
## Methods
- The paper used a targeted literature review of peer-reviewed and gray literature on obesity medications in the US, plus clinical guidelines, professional society publications, purchaser coalition white papers, and patient advocacy materials.
- The authors conducted 14 interviews of 45 minutes each with policy experts, including pharmacy benefit managers, manufacturers, patient advocacy groups, purchasers, benefit consultants, and state/Medicaid experts; they also note a 2-day meeting in December 2024 with senior policy leaders from 26 payer and life science companies and other stakeholders.
- The analysis is a policy review: it synthesizes expert input and literature to compare market strategies and federal policy interventions, weighing advantages, barriers, and unintended consequences rather than testing an empirical intervention.
## Limitations
- The paper states that no single market action or policy reform is a “silver bullet,” and that the evidence base is incomplete for several proposed approaches, including step therapy, time-limited treatment, screening tools, and carve-out programs.
- It explicitly notes that there are no publicly available data for some outcomes of interest, including outcomes after switching from one GLP-1 to another, and that there are no rigorous trials for some carve-out program components.
- Evident from the text: this is not an outcome study but a narrative/policy analysis based on literature and expert interviews, so its conclusions are dependent on rapidly changing coverage, pricing, and regulatory conditions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 17 Not valid · 68 Not checked · 92 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High rates of discontinuation of treatment with GLP-1 drugs have been noted in observational analyses.”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Background > The advent of GLP-1 receptor agonists
What the sources say
- Supportedcites [16] Gleason PP, Urick BY, Marshall LZ Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. JMCP 30(8), 860– 867 (2024). 38717042 PMC11293763 source
The Discussion reports that fewer than one-third of commercially insured adults with obesity and without diabetes remained on GLP-1 therapy after one year. The Conclusions describe a substantial portion of patients apparently discontinuing therapy within the first year, supporting the claim about high discontinuation rates in observational analyses. (LLM, conf=0.94)
- Not matchedcites [17] Marshall LZ, Urick BY, Friedlander N Two-year persistent glucagon-like peptide-1 agonist obesity without diabetes treatment: clinical outcomes among commercially insured. In: AMCP Annual Meeting, Prime Therapeutics, TX, USA (2025). Available at: https://www.primetherapeutics.com/documents/d/primetherapeutics/4085-d_amcp_spring25_glp1apersistentclinicaloutcomes_r4-1
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, BMI, the main patient characteristic being used for limiting coverage eligibility, is an imperfect measure of obesity-related health risks [65].”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Potential market strategies > Enhanced prior authorization & formulary management
What the sources say
- Supportedcites [65] Smith BM, Criminisi A, Sorek N Modeling health risks using neural network ensembles. PLoS One 19(10), e0308922 (2024). 39383158 PMC11463747 sourceExperimental — accuracy not yet measured
The Introduction says BMI alone can misclassify risk because it cannot distinguish body fat from lean tissue. The Results and discussion section also finds that BMI alone gives an incomplete picture of health risk and that models using multiple biometrics predict risk better. The paper supports the claim about BMI’s limitations; the coverage-eligibility context is the citing authors’ framing. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but exercise is an important complement to GLP-1 use, particularly among the elderly, because of the potential for muscle-wasting and bone mineral density side effects [68,69].”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Potential market strategies > Enhanced prior authorization & formulary management
What the sources say
- Not checked — no full text of the sourcecites [68] Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet 12(11), 785– 787 (2024). 39265590 source
- Partly supportedcites [69] Jensen SB, Sørensen V, Sandsdal RM Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA 7(6), e2416775 (2024). PMC11200146 38916894 sourceExperimental — accuracy not yet measured
The Discussion reports that exercise alongside liraglutide preserved hip and spine bone mineral density, supporting exercise as a complement to GLP-1 treatment for bone health. The Limitations section cautions that the trial included adults aged 18–65 and may not generalize to older individuals. The Results report preserved lean mass with combination treatment, but do not establish muscle-wasting as a liraglutide side effect. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Table 1, current estimated annual net prices for GLP-1s used for obesity in the US commercial market range from approximately $8000 to $9000.”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Background > The advent of GLP-1 receptor agonists
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but interest in exploring this approach, should further evidence demonstrate its effectiveness, is high across purchasers and payers we interviewed.”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Potential market strategies > Enhanced prior authorization & formulary management
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
62 more claims
Create a free account to see all 184 claims and to verify the 25 references still open.
- It may state two separate claims as one. 60
- Probably not a substantial claim. 79
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Potential market strategies > Carve-out programs for obesity management services
“In initial nonpeer-reviewed findings on a small number of patients after launch, Connecticut has reported meaningful reductions in weight loss among participants [78].”
§ Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US > Potential market strategies > Carve-out programs for obesity management services
“Among patients enrolled in Flyte for at least 6 months, weight decreased by an average of 10% overall. Approximately 50% of patients were prescribed an OM other than a GLP-1 drug. Average weight loss was 12% on patients treated with GLP-1s and 4% among others, although it is unknown what proportion of patients met their weight loss goal across groups.”
Citations
Cites
The Stigma of Obesity: A Review and Update
Puhl, R. M., & Heuer, C. A. (2009) · Obesity · doi:10.1038/oby.2008.636 · Cited by 3,323 · cited 1×
“People living with obesity are also subject to widespread stigma that has always overshadowed care for this chronic condition [12 , 13] .”
Impact of weight bias and stigma on quality of care and outcomes for patients with obesity
Phelan, S. M., Burgess, D. J., Yeazel, M. W., Hellerstedt, W. L., Griffin, J. M., & van Ryn, M. (2015) · Obesity Reviews · doi:10.1111/obr.12266 · Cited by 1,361 · cited 1×
“People living with obesity are also subject to widespread stigma that has always overshadowed care for this chronic condition [12 , 13] .”
Association of body mass index with health care expenditures in the united states by age and sex
Ward, Z. J., Bleich, S. N., Long, M. W., & Gortmaker, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247307 · Cited by 428 · cited 1×
“Obesity also drives increased healthcare costs, with the direct costs of obesity now estimated at between $ 170 and $ 260 billion per year in the U.S [8 , 9] .”
Direct medical costs of obesity in the United States and the most populous states
Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400 · cited 1×
“Obesity also drives increased healthcare costs, with the direct costs of obesity now estimated at between $ 170 and $ 260 billion per year in the U.S [8 , 9] .”
Muscle matters: The effects of medically induced weight loss on skeletal muscle
Prado, C. M., Phillips, S. M., Gonzalez, M. C., & Heymsfield, S. B. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00272-9 · Cited by 177
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23332 · Cited by 172 · cited 1×
“In a study from Prime Therapeutics of over 16 million commercially insured people in 2021 who did not have diabetes but were treated with GLP-1 drugs, adherence to treatment over 1 year was only 36% for patients who initiated treatment with Wegovy, and 47% with Ozempic [16] .”
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Bhattacharya, J., & Sood, N. (2011) · The Journal of Economic Perspectives · doi:10.1257/jep.25.1.139 · Cited by 141 · cited 1×
“Broader economic and societal costs are undoubtedly far higher [10] .”
Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)
Latif, W. A., Lambrinos, K. J., & Rodríguez, R. (2021) · StatPearls · Cited by 119
Patents and regulatory exclusivities on GLP-1 receptor agonists
Alhiary, R., Kesselheim, A. S., Gabriele, S., Beall, R. F., Tu, S. S., & Feldman, W. B. (2023) · JAMA · doi:10.1001/jama.2023.13872 · Cited by 67 · cited 1×
“Research has shown that brand-name GLP-1 manufacturers have obtained a median of 19.5 patents per GLP-1 receptor agonist and secured a median of 18.3 years of expected protection, with more than half of all patents obtained on the delivery devices rather than active ingredients [24] .”
Influential
Research works printed but not linked: 18
- Institute for Clinical and Economic Review. Medications for obesity management: effectiveness and value. (2022). Available at: https://icer.org/wp-content/uploads/2022/03/ICER_Obesity_Final_Evidence_Report_and_Meeting_Summary_122223.pdf
- Marshall LZ, Urick BY, Friedlander N Two-year persistent glucagon-like peptide-1 agonist obesity without diabetes treatment: clinical outcomes among commercially insured. In: AMCP Annual Meeting, Prime Therapeutics, TX, USA (2025). Available at: https://www.primetherapeutics.com/documents/d/primetherapeutics/4085-d_amcp_spring25_glp1apersistentclinicaloutcomes_r4-1
- Sharma A. Eli Lilly resolves shortage for tirzepatide, potentially ending compounders' run. Endpoints News (2024). Available at: https://endpts.com/eli-lilly-resolves-shortage-for-tirzepatide-ending-compounders-run/
- Sutter S. US FDA employs familiar strategy in ending Novo's Wegovy, Ozempic shortage. Citeline (2025). Available at: https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/us-fda-employs-familiar-strategy-in-ending-novos-wegovy-ozempic-shortage-XWRMJ2WTPNCXTEHHJEXJAJE2QY/
- Carbajal E. 1% of ACA health plans cover GLP-1s for weight loss. KFF (2024). Available at: https://www.beckerspayer.com/payer/1-of-aca-health-plans-cover-glp-1s-for-weight-loss-kff/
- Wilson R. Employers are worried about GLP-1s – most cover them anyway. Becker's Payer Issues (2024). Available at: https://www.beckerspayer.com/payer/employers-are-worried-about-glp-1s-most-cover-them-anyway/
- Goforth A. North Carolina ends coverage of new weight loss drugs for 750,000 state employees. BenefitsPRO (2024). Available at: https://www.benefitspro.com/2024/05/17/north-carolina-ends-coverage-of-glp-1-weight-loss-drugs-for-750000-state-employees/?slreturn=20241106182539
- Sellers M. Blue Cross Blue Shield of Massachusetts faces record-breaking $400 million operating loss in 2024. Insurance Business Magazine (2025). Available at: https://www.insurancebusinessmag.com/us/news/life-insurance/blue-cross-blue-shield-of-massachusetts-faces-recordbreaking-400-million-operating-loss-in-2024-526958.aspx
- McGough M, Lo J, Tevis D, Rae M, Cox C. How many adults with private health insurance could use GLP-1 drugs. Peterson-KFF (2024). Available at: https://www.healthsystemtracker.org/brief/how-many-adults-with-private-health-insurance-could-use-glp-1-drugs/
- FormHealth. Dedicated clinical care to make lasting change. FormHealth (2025). Available at: https://www.formhealth.co/how-it-works
- Phenomix Sciences. Phenomix Sciences and InformedDNA partner to advance genetics-driven obesity care. Phenomix Sciences (2024). Available at: https://www.phenomixsciences.com/about/press/phenomix-sciences-and-informeddna-partner-advance-genetics-driven-obesity-care#:∼:text=The%20MyPhenome%20test%20is%20a,treatments%2C%20including%20GLP%2D1s
- Palmer K. During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less. STAT (2025). Available at: https://www.statnews.com/2025/01/16/jp-morgan-conference-virtual-care-companies-glp-plans/
- Calibrate. Calibrate delivers longitudinal real-world outcomes with sustained weight loss and metabolic health improvements. Calibrate (2025). calibrate.cdn.priscmic.io. Available at: https://calibrate.cdn.prismic.io/calibrate/Z4VCK5bqstJ99ZFD_2025ResultsReportWhitePaper-1-.pdf
- Institute for Clinical and Economic Review. Cornerstones of ‘fair’ drug coverage. (2020). Available at: https://icer.org/assessment/cornerstones-of-fair-drug-coverage-2020/
- Baghdadi R. Medicaid best price. HealthAffairs (2017). Available at: https://www.healthaffairs.org/content/briefs/medicaid-best-pricehttps://www.healthaffairs.org/content/briefs/medicaid-best-price
- Fitch ME. CT state employees losing weight on medication, but costs top $35 million. Inside Investigator (2024). Available at: https://insideinvestigator.org/ct-state-employees-losing-weight-on-medication-but-costs-top-35-million/
- Pifer R. Why Cigna is capping cost increases for pricey GLP-1 weight loss drugs. MedTechDive (2024). Available at: https://www.medtechdive.com/news/cigna-glp-1-cost-cap-employers-pbm/709770/
- Nania R. Medicare unveils first negotiated prices for 10 of the costliest medications. AARP (2024). Available at: https://www.aarp.org/politics-society/advocacy/info-2024/medicare-drug-price-list.html
Cited by
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2026) · BMC Medicine · doi:10.1186/s12916-025-04528-7 · Cited by 41
Rethinking the Diabetes–Cardiovascular Disease Continuum: Toward Integrated Care
Caturano, A., Morciano, C., Zielińska, K., Russo, V., Perrone, M. A., Berra, C., & Conte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186678 · Cited by 26
“U.S. and international assessments also emphasize that affordability and access can be improved via outcomes-based contracts and budget-guardrails that balance short-term budgets with long-term value, especially relevant as GLP-1 class use expands [77].”
Krug, I., Dang, A. B., Portingale, J., Li, Y., & Won, Y. Q. (2025) · Nutrients · doi:10.3390/nu17233735 · Cited by 23
“In the United States, monthly costs typically range from USD 500–1200 (up to ~USD 9000 annually) when not covered by insurance [107], while in Australia, private prescriptions for weight loss commonly cost AUD 130–600 per month [108,109].”
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
Chao, A. M., Gilden, A. H., & Wadden, T. A. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004871 · Cited by 16
Metadata
- Authors
- Pearson, S. D., Whaley, C. M., & Emond, S. K.
- Affiliations
- Institute for Clinical and Economic Review (US)
- Brown University (US)
- Corresponding author
- Emond, Sarah K
- Venue
- Journal of Comparative Effectiveness Research
- Publisher
- Becaris Publishing Limited
- Published
- 2025-09
- Volume
- 14
- Issue
- 9
- Pages
- e250083-e250083
- ISSN
- 2042-6305 (ISSN-L)
- 2042-6313
- PMC
- PMC12403326
- OpenAlex
- W4412191076
- Cited by
- 55
- References
- 22
- Citations by year
- 2026: 52 · 2025: 3
- FWCI
- 37.17
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Comparative Effectiveness Research (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- GLP-1 receptor agonists, anti-obesity drugs, drug pricing, access to medicines, health policy, pharmaceutical market, insurance coverage, payment models, cost-effectiveness, health equity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Health Policy, Health Services Accessibility, Humans, Obesity, United States, Drug Costs, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. https://app.cochat.ai/papers/10.57264/cer-2025-0083
- The paper
- Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025). Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.